TriSalus Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Revenue	18.51	12.4	8.4	0
Revenue Growth (YoY)	49.31%	47.58%	-	-
Cost of Revenue	2.61	2.26	1.19	0
Gross Profit	15.91	10.14	7.21	0
Selling, General & Admin	40.55	25.22	17.02	0.11
Research & Development	29.51	21.36	14.22	0
Other Operating Expenses	0.38	0.42	-0.75	0
Operating Expenses	70.44	47	30.49	0.11
Operating Income	-54.53	-36.86	-23.29	-0.11
Interest Expense / Income	0.02	0	1.76	0
Other Expense / Income	4.48	10.32	3.8	0.6
Pretax Income	-59.03	-47.18	-28.84	-0.71
Income Tax	0.01	0.01	0	0
Net Income	-59.04	-47.19	-28.85	-0.71
Shares Outstanding (Basic)	9	0	0	8
Shares Outstanding (Diluted)	9	0	0	8
Shares Change	2934.71%	41.31%	-97.37%	-
EPS (Basic)	-6.73	-161.55	-131.65	-0.09
EPS (Diluted)	-6.73	-161.55	-131.65	-0.09
Free Cash Flow	-51.17	-33.1	-23.96	-0.68
Free Cash Flow Per Share	-5.45	-106.91	-109.33	-0.08
Gross Margin	85.93%	81.79%	85.80%	-
Operating Margin	-294.58%	-297.30%	-277.18%	-
Profit Margin	-318.93%	-380.60%	-343.35%	-
Free Cash Flow Margin	-276.41%	-266.97%	-285.14%	-
EBITDA	-58.31	-46.78	-26.62	-0.71
EBITDA Margin	-315.01%	-377.31%	-316.83%	-
Depreciation & Amortization	0.7	0.4	0.46	0
EBIT	-59.01	-47.18	-27.08	-0.71
EBIT Margin	-318.80%	-380.52%	-322.35%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).